A5095040789- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Pharmacological Effects of Natural Compounds
- Chromatography in Natural Products
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging Techniques and Applications
- Ginseng Biological Effects and Applications
- Endometrial and Cervical Cancer Treatments
- CAR-T cell therapy research
- Advanced Radiotherapy Techniques
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Glycosylation and Glycoproteins Research
- Lymphoma Diagnosis and Treatment
Nanjing University of Chinese Medicine
2025
Qilu Hospital of Shandong University
2024
QL1604 is a highly selective, humanized monoclonal antibody against programmed death protein 1. We assessed the efficacy and safety of plus chemotherapy as first-line treatment in patients with advanced cervical cancer.
Abstract Purpose Anatomical and other changes during radiotherapy will cause inaccuracy of dose distributions, therefore the expectation for online adaptive radiation therapy (ART) is high in effectively reducing uncertainties due to intra‐variation. However, ART requires extensive time effort. This study investigated an assessment workflow based on fractional cone‐beam computed tomography (CBCT) images. Methods Image registration, synthetic CT (sCT) generation, auto‐segmentation,...
3578 Background: Iparomlimab, a novel anti-PD-1 antibody, demonstrated robust anti-tumor activity and well tolerated safety in pts with unresectable/metastatic dMMR/MSI-H solid tumors. At median follow-up of 17 mo, iparomlimab treatment durable clinical benefit. Methods: This phase II study (NCT04326829) enrolled pathologically diagnosed as Pts received (200 mg, iv, Q3W; 3 mg/kg for body weight <40 kg). The primary endpoint was confirmed objective response rate (ORR) assessed by...
<h3>Background</h3> CCR8 is an important chemokine receptor expressed on intratumoral regulatory T cell (Tregs). Selective depletion of Tregs by targeting may be a promising therapeutic approach. QLP 2117 highly selective IgG1 antibody against with enhanced antibody-dependent cell-mediated cytotoxicity glycoengineering. Here we present the results ongoing phase 1a trial QLP2117 in advanced solid tumors. <h3>Methods</h3> The 1 recruited patients locally advanced, recurrent or metastatic...